Table 4.
Long-term complications after lung transplant.
| All patients (n = 20) | With telomere shortening (n = 12) | Without telomere shortening (n = 8) | P-value | |
|---|---|---|---|---|
| >1 complication after transplant (n, %)* (n = 20) | 18 (90.0) | 11 (91.7) | 7 (87.5) | 1.000 |
| Post-operative complications in the first 24 h (n, %) | 18 (90.0) | 10 (83.3) | 8 (100) | 0.495 |
| Complications during the first month (n, %) | 17 (89.5) | 9 (81.9) | 8 (100) | 0.485 |
| Complications after the first month (n, %) (n = 19) | 18 (94.7) | 11 (100) | 7 (87.5) | 0.421 |
| Allograft dysfunction (n, %) | 8 (42.1) | 3 (27.3) | 5 (62.5) | 0.181 |
| Nephrological complications (n, %) | 7 (35.0) | 4 (33.3) | 3 (37.5) | 1.000 |
| Positive pre-transplant CMV serology (n, %) | 18 (90.0) | 11 (91.7) | 7 (87.5) | 1.000 |
| Post-transplant CMV replication (n, %) (n = 19) | 14 (73.7) | 7 (63.6) | 7 (87.5) | 0.338 |
| Hematological alterations due to CMV treatment (n, %) (n = 15) | 4 (26.7) | 3 (33.3) | 1 (16.7) | 0.604 |
| CMV negativity after treatment (n, %) (n = 16) | 9 (56.2) | 4 (44.4) | 5 (71.4) | 0.358 |
| Infectious complications (n, %) | 12 (60.0) | 6 (50.0) | 6 (75.0) | 0.373 |
| Hematological complications (n, %) | 6 (30.0) | 4 (33.3) | 2 (25.0) | 1.000 |
| Endocrine complications (n, %) | 15 (75.0) | 8 (66.7) | 7 (87.5) | 0.603 |
| Hospital admissions after transplant [median (Q1;Q3)] (n = 19) | 1.0 (0.00;3.00) | 2.00 (1.00;3.00) | 0.00 (0.00;1.25) | 0.033 |
*
>1 complication at any time after lung transplant.